SK Bioscience's next-generation pneumococcal vaccine enters 1st clinical trial
SK Bioscience's next-generation pneumococcal vaccine enters 1st clinical trial
  • Lee Jun-sung
  • 승인 2018.12.13 11:21
  • 댓글 0
이 기사를 공유합니다

SK Bioscience announced on Dec. 12 that the next-generation pneumococcal vaccine, which is being developed jointly with Sanofi Pasteur, passed the U.S. Food and Drug Safety Administration's approval of its clinical trial plan, called the IND, and entered the first clinical trial stage early this month. 

SK Chemical, the parent company of SK Bioscience, signed a contract with Sanofi Pasteur, a global vaccine company, to jointly develop and sell the next-generation pneumococcal  vaccines in 2014.

Under the existing contract, Sanofi Pasteur will cooperate with SK Bioscience for the overall development process of pneumococcal vaccine, including approval and marketing.

According to the global market research firm, Data Monitor Healthcare, the market for pneumococcal vaccine amounted to about 5.2 trillion won in 2016, only in the United States, Japan and five major EU countries. It is expected to grow to about 7.1 trillion won by 2025.

"Our goal of creating a premium vaccine that leads the global market with the next-generation innovative technology is becoming a reality. We will promote the health of mankind through innovative vaccine technology," said SK Bioscience CEO Ahn Jae-yong.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: / Editorial Div. 02-578-0434 / 010-2442-9446. Email:
  • Publisher: Monica Younsoo Chung. CEO: Lee Kap-soo. Editor: Jung Yeon-jin. Juvenile Protection Manager: Yeon Choul-woong.
  • IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.